Osimertinib and Other Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitors for Untreated Advanced EGFR-Mutated Non-small Cell Lung Cancer in Japan: Analyzing Updated Data from the TREAD project 01

Osimertinib and Other Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitors for Untreated Advanced EGFR-Mutated Non-small Cell Lung Cancer in Japan: Analyzing Updated Data from the TREAD project 01 - Osimertinib and Other Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitors for Untreated Advanced EGFR-Mutated Non-small Cell Lung Cancer in Japan: Analyzing Updated Data from the TREAD project 01

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000050552

Enrollment

500

Registered

2023-03-09

Start date

2023-03-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced EGFR-mutated non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients were serially enrolled from the TREAD-01 database. Patients with cytologically or pathologically confirmed non-small cell lung cancer, disease due to sensitizing EGFR mutations (Del19 or L858R), including patients with compound EGFR mutations, who were at least 20 years old at the start of treatment were eligible for enrollment.47 hospitals participating in the TREAD project in the TREAD project received first-line treatment with gefitinib, erlotinib, afatinib, dacomitinib, or osimertinib and at least one dose of osimertinib during the entire treatment period from April 2010 to 2022.

Exclusion criteria

Exclusion criteria: EExclusion criteria include: de novo EGFR T790 M mutation, active multiple cancers, failure to provide informed consent (opting to opt-out), poor data extraction (e.g., missing details of previous cancer treatment at other hospitals or individual patient data), simultaneous and metachronous double cancers other than in situ/intramucosal cancer cured by local treatment or endoscopic lesions diagnosed as in situ cancer, and disease-free for 5 years or less.

Design outcomes

Primary

Measure	Time frame
OS	—

Countries

Japan

Contacts

Public ContactMakoto Hibino

Shonan Fujisawa Tokushukai Hospital Resoiratory medicne

m-hibino@ctmc.jp0466351177

Outcome results